心肌肌球蛋白抑制剂在梗阻性肥厚型心肌病治疗中的研究现状  

Cardiac Myosin Inhibitors in Treatment of Obstructive Hypertrophic Cardiomyopathy

作　　者：姚舜禹 罗素新[1] 黄毕 YAO Shunyu;LUO Suxin;HUANG Bi(Department of Cardiology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400000,China)

机构地区：[1]重庆医科大学附属第一医院心血管内科,重庆400000

出　　处：《心血管病学进展》2024年第5期397-401,共5页Advances in Cardiovascular Diseases

基　　金：重庆英才计划项目(cstc2022ycjh-bgzxm0231);重庆医科大学未来医学青年创新团队支持计划(0184)。

摘　　要：梗阻性肥厚型心肌病(OHCM)是一种常染色体显性遗传病,以室间隔不对称性肥厚为主要表现,传统的治疗方法主要以改善症状为主,缺乏针对梗阻引起的血流动力学异常的特异性药物。随着对疾病研究的不断深入及药物研发的进展,针对梗阻性肥厚的病理生理学基础的药物——心肌肌球蛋白抑制剂应运而生。目前的试验结果表明,心肌肌球蛋白抑制剂可有效减轻左心室流出道梗阻,改善患者的纽约心功能分级和生活质量。该药的短期有效性和安全性已被证实,但长期的疗效目前尚在进行临床试验评估。现就心肌肌球蛋白抑制剂在OHCM中的作用机制并结合近期的临床试验结果及在未来OHCM中的治疗地位进行综述。Obstructive hypertrophic cardiomyopathy(OHCM)is an autosomal dominant genetic disease characterized by asymmetric hypertrophy of the interventricular septum.Traditional treatment methods mainly focus on improving symptoms and lack specific drugs for hemodynamic change caused by obstruction.With the deepening of research on the disease and the progress of drug development,drugs based on the pathophysiology of obstructive hypertrophy—Cardiac myosin inhibitors have emerged.Current experimental results show that cardiac myosin inhibitors can effectively reduce left ventricular outflow tract obstruction,improve patients’New York Heart function assessment and quality of life.The short-term efficacy and safety of the drug have been confirmed,but the long-term efficacy is currently being evaluated in clinical trials.This article reviews the mechanism of cardiac myosin inhibitors in OHCM,combined with recent clinical trial results and the treatment status of OHCM in the future.

关 键 词：梗阻性肥厚型心肌病 心肌肌球蛋白抑制剂 流出道梗阻 短期预后 

分 类 号：R542.2[医药卫生—心血管疾病]